Vertex Pharmaceuticals Incorporated
VRTX
$489.10
$3.210.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.66% | 10.06% | 8.76% | 10.61% | 10.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.66% | 10.06% | 8.76% | 10.61% | 10.51% |
| Cost of Revenue | 12.90% | 17.14% | 19.32% | 20.61% | 22.66% |
| Gross Profit | 10.66% | 4.60% | 1.03% | 3.68% | 2.27% |
| SG&A Expenses | 25.96% | 40.67% | 32.41% | 27.57% | 20.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.57% | 21.78% | 21.97% | 22.04% | 22.17% |
| Operating Income | 6.62% | -3.87% | -6.11% | -1.52% | -1.62% |
| Income Before Tax | -94.33% | -93.98% | -95.01% | 14.35% | 3.48% |
| Income Tax Expenses | 3.14% | -11.90% | -25.15% | -17.75% | -16.50% |
| Earnings from Continuing Operations | -114.80% | -113.83% | -114.56% | 23.31% | 8.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.80% | -113.83% | -114.56% | 23.31% | 8.96% |
| EBIT | 6.62% | -3.87% | -6.11% | -1.52% | -1.62% |
| EBITDA | 6.65% | -2.70% | -5.01% | -0.75% | -1.10% |
| EPS Basic | -114.72% | -113.76% | -114.46% | 22.70% | 8.28% |
| Normalized Basic EPS | 4.80% | -1.35% | -0.73% | 5.91% | 7.77% |
| EPS Diluted | -115.87% | -114.98% | -115.73% | 22.77% | 8.33% |
| Normalized Diluted EPS | 5.00% | -1.14% | -0.44% | 5.99% | 7.85% |
| Average Basic Shares Outstanding | 0.10% | 0.19% | 0.34% | 0.48% | 0.62% |
| Average Diluted Shares Outstanding | -0.14% | -0.05% | 0.02% | 0.40% | 0.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |